Reprinted from hcrenewal.blogspot.com
This week's spectacle in Washington, DC was a nearly unanimous Democratic minority in the Senate blocking a proposal for expedited consideration of multinational trade agreements favored by the Republican majority, but also by the Democratic President and his trade negotiators (look here). Democrats mainly based their actions on perceptions that the trade agreements favored multinational corporations over people.
Corporate Friendly Trade Agreements
The US has been negotiating two major multinational trade agreements, the Trans-Pacific Partnership (TPP) and the Transatlantic Trade and Investment Partnership (TTIP) for years.
will benefit the wealthiest sliver of the American and global elite at the expense of everyone else.
This seems surprising, since most people think of trade agreements solely in terms of their effects on tariffs, not a big concern for health care and public health professionals. However, Stiglitz noted
Tariffs around the world are already low. The focus has shifted to 'nontariff barriers,' and the most important of these -- for the corporate interests pushing agreements -- are regulations. Huge multinational corporations complain that inconsistent regulations make business costly. But most of the regulations, even if they are imperfect, are there for a reason: to protect workers, consumers, the economy and the environment.
What's more, those regulations were often put in place by governments responding to the democratic demands of their citizens. Trade agreements' new boosters euphemistically claim that they are simply after regulatory harmonization, a clean-sounding phrase that implies an innocent plan to promote efficiency. One could, of course, get regulatory harmonization by strengthening regulations to the highest standards everywhere. But when corporations call for harmonization, what they really mean is a race to the bottom.
In the US, and other developed countries, there are lots of regulations that have major effects on health care and public health. Changes in these regulations, or their implementation, could have major effects again on health care and the public health. So those interested in health care and public health ought to be concerned about how such trade agreements could affect such regulation.
One of Stiglitz's concerns was that the trade agreement would allow international tribunals that could override national law, particularly law promoting public health:
What we know of ... particulars [of the TTP] only makes it more unpalatable. One of the worst is that it allows corporations to seek restitution in an international tribunal, not only for unjust expropriation, but also for alleged diminution of their potential profits as a result of regulation. This is not a theoretical problem. Philip Morris has already tried this tactic against Uruguay, claiming that its antismoking regulations, which have won accolades from the World Health Organization, unfairly hurt profits, violating a bilateral trade treaty between Switzerland and Uruguay.
In fact, Philip Morris has also used such tribunals to overturn Australian laws meant to discourage smoking for public health purposes. The details of the Philip Morris case summarized in May, 2015 in an article by Lauren Carasik in Foreign Policy, show the major public health implications of such trade tribunals,